Adaptimmune Therapeutics Ltd

Adaptimmune is a leader in T cell receptor therapy to treat cancer.

The company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumours.

Its technology was developed at Oxford University in the early 1990s and a business called Avidex was spun out. Adaptimmune was spun out of that company and in 2015 it launched on the

New York Nasdaq, raising $176 million.

It has a sister company (also in this listing), Immunocore which focuses on soluble TCR technology.

In September last year, Adaptimmune announced that it had entered into a strategic collaboration and licence agreement with Genentech, a member of the Roche Group to develop and commercialise allogeneic cell therapies to treat multiple oncology indications.